Aktis Oncology

AKTS · NASDAQ

$16.08+$0.97 (+6.42%)TodayMarket closed ·
Prev close $15.11

Who owns AKTS

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 62.1% of AKTS’s shares.

  • Eli Lilly and Company11.9%
  • VV Manager LLC10.9%
  • MPM BioImpact LLC9.1%
  • EcoR1 Capital, LLC9.0%
  • Next 6 largest institutions21.2%
  • All other shareholders37.9%
Top institutional holders of AKTS
HolderShares% of shares
Eli Lilly and Company6.34M11.88%
VV Manager LLC5.83M10.92%
MPM BioImpact LLC4.84M9.06%
EcoR1 Capital, LLC4.82M9.03%
Blue Owl Capital Holdings LP3.07M5.75%
T. Rowe Price Investment Management, Inc.2.05M3.84%
Wellington Management Company, LLP1.97M3.68%
RTW Investments L.P.1.59M2.98%
BlackRock Institutional Trust Company, N.A.1.33M2.49%
RA Capital Management, LP1.31M2.46%

Largest mutual fund holders

Top mutual fund holders of AKTS
HolderShares% of shares
Vanguard Health Care Fund1.95M3.66%
T. Rowe Price Small Cap Stock Fund676.58K1.27%
Vanguard Total Stock Market Index Fund585.13K1.10%
iShares Russell 2000 ETF548.49K1.03%
Eventide Healthcare & Life Sciences Fund507.00K0.95%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders sold $3.23M (11 trades) of AKTS on the open market, with no buys.

Latest AKTS insider transactions
InsiderTypeSharesValue
Czibere AkosOption exercise12.50K—
Czibere AkosSale7.40K$155.65K
Czibere AkosSale5.10K$102.97K
Czibere AkosOption exercise12.50K$61.87K
Herrmann KenOption exercise1.35K—
Herrmann KenOption exercise3.51K—
Herrmann KenSale1.35K$33.16K
Herrmann KenSale3.51K$86.12K
Herrmann KenOption exercise1.35K$2.58K
Herrmann KenOption exercise3.51K$280

Short interest

Settled Sep 30, 2026

Shares short
4.72M
Days to cover
7.30
% of shares outstanding
8.83%
Average daily volume
645.72K
Change since last report
+45.0%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.